JP2007517885A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007517885A5 JP2007517885A5 JP2006549374A JP2006549374A JP2007517885A5 JP 2007517885 A5 JP2007517885 A5 JP 2007517885A5 JP 2006549374 A JP2006549374 A JP 2006549374A JP 2006549374 A JP2006549374 A JP 2006549374A JP 2007517885 A5 JP2007517885 A5 JP 2007517885A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- adamantane
- component
- eye
- neuroprotective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 claims 66
- 239000000203 mixture Substances 0.000 claims 41
- 230000000324 neuroprotective effect Effects 0.000 claims 38
- 241001465754 Metazoa Species 0.000 claims 13
- 230000000694 effects Effects 0.000 claims 11
- 210000001525 retina Anatomy 0.000 claims 8
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims 6
- 229920002125 Sokalan® Polymers 0.000 claims 6
- 239000000783 alginic acid Substances 0.000 claims 6
- 235000010443 alginic acid Nutrition 0.000 claims 6
- 229920000615 alginic acid Polymers 0.000 claims 6
- 229960001126 alginic acid Drugs 0.000 claims 6
- 150000004781 alginic acids Chemical class 0.000 claims 6
- 239000004584 polyacrylic acid Substances 0.000 claims 6
- 238000011200 topical administration Methods 0.000 claims 6
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims 5
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims 5
- 229960004640 memantine Drugs 0.000 claims 5
- 150000001412 amines Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 3
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims 3
- 108010010803 Gelatin Proteins 0.000 claims 3
- 241000282412 Homo Species 0.000 claims 3
- 229920000805 Polyaspartic acid Polymers 0.000 claims 3
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 3
- 229960003805 amantadine Drugs 0.000 claims 3
- 229920006321 anionic cellulose Polymers 0.000 claims 3
- 229920006320 anionic starch Chemical class 0.000 claims 3
- 239000008365 aqueous carrier Substances 0.000 claims 3
- 229920000159 gelatin Polymers 0.000 claims 3
- 239000008273 gelatin Substances 0.000 claims 3
- 229940014259 gelatin Drugs 0.000 claims 3
- 235000019322 gelatine Nutrition 0.000 claims 3
- 235000011852 gelatine desserts Nutrition 0.000 claims 3
- 229920002674 hyaluronan Polymers 0.000 claims 3
- 229960003160 hyaluronic acid Drugs 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 235000019426 modified starch Nutrition 0.000 claims 3
- 108010064470 polyaspartate Proteins 0.000 claims 3
- 229960000888 rimantadine Drugs 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 2
- 231100000252 nontoxic Toxicity 0.000 claims 2
- 230000003000 nontoxic effect Effects 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 208000003098 Ganglion Cysts Diseases 0.000 claims 1
- 208000005400 Synovial Cyst Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000006727 cell loss Effects 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 229920000447 polyanionic polymer Polymers 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/752,125 US20050147584A1 (en) | 2004-01-05 | 2004-01-05 | Compositions and methods comprising memantine and polyanionic polymers |
| US10/941,272 US20050031652A1 (en) | 2003-02-25 | 2004-09-14 | Compositions and methods comprising memantine and polyanionic polymers |
| PCT/US2005/000249 WO2005067891A1 (en) | 2004-01-05 | 2005-01-04 | Compositions comprosing memantine and polyanionic polymers for administration to the eye |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007517885A JP2007517885A (ja) | 2007-07-05 |
| JP2007517885A5 true JP2007517885A5 (enExample) | 2008-02-21 |
Family
ID=34798997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006549374A Withdrawn JP2007517885A (ja) | 2004-01-05 | 2005-01-04 | 眼に投与するためのメマンチンおよびポリアニオン性ポリマーを含む組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20050031652A1 (enExample) |
| EP (1) | EP1701700A1 (enExample) |
| JP (1) | JP2007517885A (enExample) |
| AU (1) | AU2005204365A1 (enExample) |
| BR (1) | BRPI0506689A (enExample) |
| CA (1) | CA2552521A1 (enExample) |
| WO (1) | WO2005067891A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050009884A1 (en) * | 1997-06-30 | 2005-01-13 | Dreyer Evan B. | Calcium blockers to treat proliferative retinal diseases |
| JP2002182418A (ja) * | 2000-12-11 | 2002-06-26 | Konica Corp | 画像形成方法、画像形成装置 |
| US20080033053A1 (en) * | 2004-07-22 | 2008-02-07 | Wolfgang Curt D | Cross-Reference To Related Applications |
| CA2575204A1 (en) * | 2004-07-26 | 2006-02-09 | Allergan, Inc. | Methods of treating ophthalmic conditions |
| US20070167527A1 (en) * | 2006-01-13 | 2007-07-19 | Burke James A | Memantine for the normalization of visual acuity deficits |
| US10954231B2 (en) | 2006-10-16 | 2021-03-23 | Bionomics Limited | Anxiolytic compounds |
| US8293737B2 (en) | 2006-10-16 | 2012-10-23 | Bionomics Limited | Anxiolytic compounds |
| WO2008098027A2 (en) * | 2007-02-06 | 2008-08-14 | Allergan, Inc. | Treatment of ischemic retinal conditions with memantine |
| EP2509596B1 (en) | 2009-12-08 | 2019-08-28 | Case Western Reserve University | Gamma aminoacids for treating ocular disorders |
| AU2012222874B2 (en) | 2011-03-02 | 2015-04-16 | Bionomics Limited | Novel small-molecules as therapeutics |
| US9133188B2 (en) | 2011-05-12 | 2015-09-15 | Bionomics Limited | Methods for preparing naphthyridines |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5554367A (en) * | 1984-10-31 | 1996-09-10 | Alcon Laboratories, Inc. | Compositions for treatment of glaucoma |
| US4911920A (en) * | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| US4738851A (en) * | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
| US5008242A (en) * | 1986-12-24 | 1991-04-16 | John Lezdey | Treatment of inflammation using 1-antichymotrypsin |
| US5221696A (en) * | 1989-03-29 | 1993-06-22 | Alcon Laboratories, Inc. | Use of monoacyl phosphoglycerides to enhance the corneal penetration of ophthalmic drugs |
| US5318780A (en) * | 1991-10-30 | 1994-06-07 | Mediventures Inc. | Medical uses of in situ formed gels |
| ES2079994B1 (es) * | 1992-10-07 | 1996-08-01 | Cusi Lab | Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica. |
| US5922773A (en) * | 1992-12-04 | 1999-07-13 | The Children's Medical Center Corp. | Glaucoma treatment |
| US5691316A (en) * | 1994-06-01 | 1997-11-25 | Hybridon, Inc. | Cyclodextrin cellular delivery system for oligonucleotides |
| US5891885A (en) * | 1996-10-09 | 1999-04-06 | Algos Pharmaceutical Corporation | Method for treating migraine |
| CA2295098A1 (en) * | 1997-06-30 | 1999-01-07 | Allergan Sales, Inc. | Calcium blockers to treat proliferative vitreoretinopathy |
| KR20020002356A (ko) * | 1998-10-27 | 2002-01-09 | 제임스 에이. 아노 | 외부 망막 손상의 치료 |
| US6258350B1 (en) * | 1999-01-20 | 2001-07-10 | Alcon Manufacturing, Ltd. | Sustained release ophthalmic formulation |
| EP1169061A1 (en) * | 1999-03-12 | 2002-01-09 | Alcon Laboratories, Inc. | Combination therapy for treating glaucoma |
| US6482854B1 (en) * | 1999-03-25 | 2002-11-19 | Massachusetts Eye And Ear Infirmary | Glaucoma treatment |
| SK282717B6 (sk) * | 2000-03-10 | 2002-11-06 | �Stav Experiment�Lnej Farmakol�Gie Sav | Spôsob prípravy ultravysokomolekulových hyalurónanov |
| CA2423354C (en) * | 2000-09-20 | 2009-12-15 | Lee Shahinian Jr. | Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications |
| US6761694B2 (en) * | 2001-12-13 | 2004-07-13 | Allergan, Inc. | Methods for measuring retinal damage |
| US6982079B2 (en) * | 2002-04-26 | 2006-01-03 | Allergan, Inc. | Compositions for treating hyperemia |
| ES2593113T3 (es) * | 2003-08-07 | 2016-12-05 | Allergan, Inc. | Composiciones para el suministro de agentes terapéuticos en los ojos y métodos para obtener y usar los mismos |
-
2004
- 2004-09-14 US US10/941,272 patent/US20050031652A1/en not_active Abandoned
-
2005
- 2005-01-04 JP JP2006549374A patent/JP2007517885A/ja not_active Withdrawn
- 2005-01-04 BR BRPI0506689-1A patent/BRPI0506689A/pt not_active IP Right Cessation
- 2005-01-04 CA CA002552521A patent/CA2552521A1/en not_active Abandoned
- 2005-01-04 WO PCT/US2005/000249 patent/WO2005067891A1/en not_active Ceased
- 2005-01-04 EP EP05705052A patent/EP1701700A1/en not_active Withdrawn
- 2005-01-04 AU AU2005204365A patent/AU2005204365A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI618539B (zh) | 無刺激性眼用聚乙烯吡咯啶酮-碘組成物 | |
| JP5244584B2 (ja) | キサンタンガムおよびブドウ糖を含有する眼科用組成物 | |
| WO2010004435A3 (en) | Ph specific solutions of sodium mycophenolic acid for the treatment of eye disorders | |
| JP2009524692A5 (enExample) | ||
| JP2007517885A5 (enExample) | ||
| JP2015025011A5 (enExample) | ||
| JP2004507496A5 (enExample) | ||
| NZ602445A (en) | Ketorolac tromethamine compositions for treating or preventing ocular pain | |
| WO2019195761A3 (en) | Pharmacological agents for treating ocular diseases | |
| JP6842794B2 (ja) | 皮膚外用製剤 | |
| JP2017523974A5 (enExample) | ||
| JP2023168547A (ja) | 眼科組成物 | |
| JP4752987B2 (ja) | 外用剤組成物 | |
| JP2023550393A (ja) | セチリジン及びトコフェルソランを含む眼科用組成物 | |
| JP2003073303A (ja) | 眼局所用液剤の清涼化作用の持続方法 | |
| TWI712429B (zh) | 水性醫藥組成物 | |
| JP2002308764A (ja) | 眼科用医薬組成物 | |
| CA2489705A1 (en) | Use of amide derivative of ge 2270 factor a3 for the treatment of acne | |
| CN104994839A (zh) | 局部眼用镇痛剂 | |
| JP2006176501A (ja) | 眼科用剤 | |
| EP1656135A1 (en) | Method and composition for treating burned skin | |
| RU2006101150A (ru) | Композиции нестероидных противовоспалительных средств для лечения патологического ангиогенеза глаз | |
| JP5957517B2 (ja) | 結膜弛緩症治療用の点眼薬 | |
| JP7778396B2 (ja) | シロスタゾールを含む組成物の脳血管疾患への応用 | |
| JP5299449B2 (ja) | 外用剤組成物 |